Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the “Southern Italy Network on Severe Asthma Therapy”
Respiration · 17.11.2026 · 105 (10) · 1141-1149
DOI: 10.1159/000550911 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Respiration, online erschienen am 10.04.2026. Verfasst von Giulia Scioscia und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy. Hauptthemen laut MEDLINE: Asthma, Biological Products, Anti-Asthmatic Agents. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Introduction
Sex influences asthma phenotypes and treatment outcomes. However, real-world data on sex-related differences in severe asthma patients treated with biologics are limited. The objective of this study was to assess sex differences in baseline characteristics and treatment outcomes in a cohort of severe eosinophilic asthma (SEA) patients treated with biologics.
Methods
We retrospectively analyzed 370 SEA patients (235 females, 135 males) treated with mepolizumab, benralizumab, or dupilumab. Clinical remission was defined as no OCS use plus at least two of: no exacerbations, ACT ≥20, or FEV1 >80%. Logistic regression was used to identify sex-specific predictors of remission at 24 months.
Results
Severe type 2 asthma showed a prevalence in females (female-to-male ratio of 1.7:1). Baseline characteristics revealed higher prevalence of obesity (p = 0.015) and osteoporosis (p = 0.006) in females, and greater tobacco exposure (p = 0.05), FeNO (p = 0.03), and nasal polyposis (p = 0.0002) in males. Males had greater reduction in FeNO (p ≤ 0.05) and more male patients stopped exacerbations at 24 months (p < 0.0001), while females showed greater FEF25–75% (p ≤ 0.05) improvement and larger IgE drops (p < 0.0001). Remission rates were similar across sexes at both 12 months (64.3% versus 74.1%; p = 0.06) and 24 months (71.5% versus 77.0%; p = 0.27). In females, remission was associated with eosinophils >300/μL (OR: 2.68; 95% CI: 1.41–5.07; p = 0.003), FeNO >50 ppb (OR: 21.05; 95% CI: 10.24–43.34; p < 0.0001), and nasal polyposis (OR: 2.74; 95% CI: 1.46–5.13; p = 0.001); obesity (OR: 0.20; 95% CI: 0.11–0.37; p < 0.0001), smoking (OR: 0.38; 95% CI: 0.21–0.70; p = 0.002), anxiety (OR: 0.47; 95% CI: 0.23–0.94; p = 0.04), and reflux (OR: 0.47; 95% CI: 0.27–0.84; p = 0.01) were negative predictors. In males, OCS dependency (OR: 0.35; 95% CI: 0.13–0.94; p = 0.03) and FEV1 <80% (OR: 0.18; 95% CI: 0.05–0.63; p = 0.004) were negative predictors.
Conclusion
Biologics were equally effective in inducing clinical remission across sexes, but different predictors influenced outcomes. Sex-aware strategies may support personalized asthma care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
- Institute of Respiratory Diseases, "Policlinico" of Foggia, Foggia, Italy.
- Division of Respiratory Diseases, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Palermo, Italy.
- Department of Medical and Surgical Sciences, School of Allergology and Clinical Immunology, University of Foggia, Foggia, Italy.
- Respiratory Medicine Unit, Policlinico "G. Rodolico-San Marco" University Hospital, Catania, Italy.
- Department of Translational Biomedicine and Neuroscience, Institute of Respiratory Disease, University of Bari "Aldo Moro", Bari, Italy.
Zitieren
APA
Scioscia, G., Quarato, C. M. I., Benfante, A., Caiaffa, M. F., Campisi, R., Carpagnano, G. E., Carrieri, I., Crimi, C., D'Amato, M., Di Bona, D., Lupia, C., Maglio, A., Quaranta, V. N., Pelaia, C., Pelaia, G., Scichilone, N., Spadaro, G., Tomesello, A., Vatrella, A., …, & Southern Italy Network on Severe Asthma Therapy (2026). Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the “Southern Italy Network on Severe Asthma Therapy”. Respiration, 105(10), 1141-1149. https://doi.org/10.1159/000550911
Vancouver
Scioscia G, Quarato CMI, Benfante A, Caiaffa MF, Campisi R, Carpagnano GE, et al. Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the “Southern Italy Network on Severe Asthma Therapy”. Respiration. 2026;105(10):1141-1149. doi:10.1159/000550911
BibTeX
@article{Scioscia2026,
author = {Scioscia, Giulia and Quarato, Carla Maria Irene and Benfante, Alida and Caiaffa, Maria Filomena and Campisi, Raffaele and Carpagnano, Giovanna Elisiana and Carrieri, Isabella and Crimi, Claudia and D'Amato, Maria and Di Bona, Danilo and Lupia, Chiara and Maglio, Angelantonio and Quaranta, Vitaliano Nicola and Pelaia, Corrado and Pelaia, Girolamo and Scichilone, Nicola and Spadaro, Giuseppe and Tomesello, Alessandra and Vatrella, Alessandro and Valenti, Giuseppe and Crimi, Nunzio and Foschino Barbaro, Maria Pia and Southern Italy Network on Severe Asthma Therapy, Southern Italy Network on Severe Asthma Therapy},
title = {Sex-Based Comparison of Remission in Patients with Severe Type 2 Asthma Treated with Biologics: A Real-World Analysis from the “Southern Italy Network on Severe Asthma Therapy”},
journal = {Respiration},
year = {2026},
volume = {105},
number = {10},
pages = {1141--1149},
doi = {10.1159/000550911}
}
EUVIMED